EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Future Care Trading Co. (9544) fair value: what the stock is really worth

We calculate from audited financials what Future Care Trading Co. is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · SA · ISIN SA15JHD4L416

FC Thin data Sep 13, 2026

Future Care Trading Co.

9544 · SR

Overvalued / MonitorQuality growthQuality is not strong enough to offset the price risk.

!Fair value 1.38 SAR · Overvalued (−10%)
Quality 67/100
!Mixed Growth (revenue 5y +5.4 %/yr)
Highly profitable · 20.7% net margin (TTM)
generates free cash flow
!Mixed vs. peers (7/12)
Wide moat 83/100
!Evidence only low, so the estimate is less certain
!Weak on valuation: 20 out of 100
Watch Future Care Trading Co. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

58.65 SAR 0.9427 SAR Fair Value 1.38 SAR Aug 2022 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.

How to read this chart

49‑month range 0.9427 SAR – 58.65 SAR · fair‑value band 0.8800 SAR – 1.68 SAR · the 1.53 SAR price screens above the 1.38 SAR fair value. Dashed = 300-day average. As of Sep 13, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Future Care Trading Co. operates as a home healthcare company in the Kingdom of Saudi Arabia. The company provides medical and home healthcare services, including home medical visits, nursing care, physical therapy, heath assistant, therapeutic nutrition, psychosocial support, and personal care services.

Show more

Future Care Trading Co. operates as a home healthcare company in the Kingdom of Saudi Arabia. The company provides medical and home healthcare services, including home medical visits, nursing care, physical therapy, heath assistant, therapeutic nutrition, psychosocial support, and personal care services. The company also operates hospitals, specialized medical complexes, mobile medical clinics, medical clinics, plasma collection centers, and laboratories. In addition, it engages in the operation of telemedicine centers, physiotherapy centers, and radiology centers; design and programming of special software and application development activities; medical rehabilitation centers; alternative and complementary medicine clinics; publishing of ready-made programs; audio-visual studio; and offers nursing aids and support medical services. Future Care Trading Co. was founded in 2015 and is headquartered in Jeddah, the Kingdom of Saudi Arabia.

Stock analysis

Future Care Trading Co. (9544) currently trades at 1.53 SAR, while our model-based Fair Value estimate is 1.38 SAR, implying the stock looks roughly 10.9% fairly valued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of 1.11 SAR per share, and 0 of the 24 models we run sit above the 1.53 SAR price.

Bear case: the Economic Profit group reads lowest at 0.2400 SAR, and 24 of the 24 models stay below the price. Evidence for this calculation is low.

Scenario range: 0.8800 SAR (bear) to 1.68 SAR (bull), the price of 1.53 SAR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 67/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Future Care Trading Co. reported revenue of 76.1M SAR in FY2025 versus 72.0M SAR in FY2021, a compound +1.4%/yr. Reported net income was 15.8M SAR in FY2025, compounding −19.1%/yr from FY2021.

Key figures

Market cap 803M SAR (≈ $214M) · P/E ratio 51.0 · P/S ratio 10.6 · EPS (TTM) 0.0300 SAR · Net margin 20.7% · Return on equity 17.4% · Return on assets (EBIT) 22.9% · Operating margin 30.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 52% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 0% fair-value upside, at −10%, 9544 screens richer than that median.

Fair Value models

Bear 0.8800 SAR Fair Value 1.38 SAR Bull 1.68 SAR
Model Each model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence Evidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF 0.3200 SAR 0.4400 SAR 0.7700 SAR 77
Growth DCF 0.3100 SAR 0.4600 SAR 0.7300 SAR 75
Owner Earnings 0.4600 SAR 0.8600 SAR 1.60 SAR 70
All 24 models by family
DCF Models
FCF DCF 0.3200 SAR 0.4400 SAR 0.7700 SAR 77
Owner Earnings 0.4600 SAR 0.8600 SAR 1.60 SAR 70
5Y Revenue Exit 0.4000 SAR 0.6500 SAR 1.19 SAR 67
5Y EBITDA Exit 0.4600 SAR 0.7800 SAR 1.41 SAR 69
5Y P/E Exit 0.5200 SAR 1.11 SAR 1.92 SAR 65
10Y Revenue Exit 0.3600 SAR 0.7400 SAR 1.00 SAR 64
10Y EBITDA Exit 0.4200 SAR 0.8700 SAR 1.67 SAR 62
10Y P/E Exit 0.4600 SAR 0.9800 SAR 1.87 SAR 58
Earnings-Based
Graham-Dodd 0.2100 SAR 1.49 SAR 2.10 SAR 63
Lynch FV 0.6100 SAR 0.8700 SAR 1.14 SAR 61
PEG = 1.0 0.6100 SAR 0.8700 SAR 1.14 SAR 57
EPV 0.3400 SAR 0.3800 SAR 0.4100 SAR 70
Multiples
P/E Multiple 0.5200 SAR 0.6900 SAR 0.8700 SAR 63
P/S Multiple 0.4000 SAR 0.5300 SAR 0.6700 SAR 58
P/B Multiple 0.4000 SAR 0.5400 SAR 0.6700 SAR 55
EV/EBIT 0.5500 SAR 0.7000 SAR 0.8600 SAR 63
EV/EBITDA 0.5200 SAR 0.6700 SAR 0.8100 SAR 64
EV/Revenue 0.4000 SAR 0.5400 SAR 0.6800 SAR 52
Asset-Based
NCAV (Graham) 0.1000 SAR 0.1300 SAR 0.1900 SAR 52
Growth DCF
Growth DCF 0.3100 SAR 0.4600 SAR 0.7300 SAR 75
Rev-Margin DCF 0.4100 SAR 0.7300 SAR 1.36 SAR 67
Economic Profit
Residual Income 0.1900 SAR 0.2400 SAR 0.5800 SAR 64
ROIC Compounder 0.4100 SAR 0.5400 SAR 0.7000 SAR 70
Growth Earnings
Growth-Adj P/E 0.7800 SAR 1.11 SAR 1.45 SAR 67

Open the full fair value analysis →

Notify me when 9544 reaches fair value

Put 9544 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 67/100

Of which business quality 65 · Market factors (momentum, volatility) 29

Profitability 66
Margins and returns on capital today
Quality Growth 79
Are margins and returns improving?
Cashflow 49
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 35
Disciplined investing over empire-building
Low Volatility 71
Calm price path (market factor)
Momentum 18
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 48
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality Growth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 80/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+41.8%
Revenue growth 3 years Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.6%
Revenue growth 5 years Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.4%
Revenue growth 7 years Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.0%
What shareholders gained per year (last 5 years) (mathematically smoothed) What the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
−59.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−59.0%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 Operating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.46% → 24%
2025 sits 52% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
⚠ Revenue per share shrinking 48.7%/yr over ~5Y (margins intact) Structural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes This turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+44.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.

Watch 9544, get fair value alerts →

Compare Future Care Trading Co. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 255 stocks

Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 67 · Top 25%
Fair Value upside −57% · Bottom 25%
Profitability
Return on equity (TTM) 17% · Top 25%
Return on assets 13% · Top 25%
Net margin (TTM) 21% · Top 25%
Operating margin (TTM) 31% · Top 25%
Growth and dividend
Revenue growth 46% · Top 25%
Dividend yield (TTM) 89.2% · Top 25%

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/E (TTM) 51.0× · Priciest 25%
P/B 2.18× · Pricier than median
P/S (TTM) 2.78× · Priciest 25%
P/FCF 24.0× · Priciest 25%
EV/EBITDA 7.4× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)20 · sector 29
FUTURE (revenue growth)100 · sector 27
PAST (return on equity)70 · sector 31
HEALTH (low debt)0 · sector 90
DIVIDEND (yield)0 · sector 42

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc HCA $426.94 $506.40 +19%
Fresenius SE FRE €45.04 €32.15 −29%
Dr. Sulaiman Al Habib Medical Services Group 4013 232.70 SAR 112.37 SAR −52%
IHH Healthcare Berhad, an investment holding company, Q0F 2.67 SGD 1.51 SGD −43%
Tenet Healthcare Corporation THC $263.69 $294.55 +12%
DaVita Inc DVA $181.55 $180.71 +0%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,850 ₹2,955 −67%
Fresenius Medical Care AG FME €38.44 €71.28 +85%
Aier Eye Hospital Group 300015 ¥8.06 ¥10.86 +35%
Max Healthcare Institute Limited MAXHEALTH ₹1,038 ₹284.87 −73%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Future Care Trading Co. Fair Value". https://www.fairvalue-calculator.com/stock/9544

Frequently asked questions

Is Future Care Trading Co. (9544) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of 1.38 SAR versus a price of 1.53 SAR, about −10% upside (fairly valued).
What is the fair value of 9544?
Our model-based fair value for Future Care Trading Co. is 1.38 SAR (as of Sep 13, 2026), built from audited fundamentals. The current price: 1.53 SAR.
What is the quality score of 9544?
Future Care Trading Co. has a Quality Score of 67/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Future Care Trading Co. (9544)?
Our model-based price target is the fair value of 1.38 SAR (as of Sep 13, 2026) from 24 valuation models. Cautious scenario 0.8800 SAR, optimistic scenario 1.68 SAR. It is a calculation from audited fundamentals, not an analyst target.
What is the Future Care Trading Co. stock forecast for 2026?
Our models put fair value at 1.38 SAR, about −10% upside versus a price of 1.53 SAR (fairly valued). Cautious scenario 0.8800 SAR, optimistic scenario 1.68 SAR. The calculation is refreshed regularly with new filings.
What is the revenue of Future Care Trading Co. (9544)?
Future Care Trading Co. reported trailing-twelve-month revenue of about 76.1M SAR (latest available figure, as of Sep 13, 2026).
What growth is priced into Future Care Trading Co. (9544)?
For today's price to be fair in a discounted-cash-flow model, Future Care Trading Co. would have to grow free cash flow by +44.0 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +5.4 % per year. As of Sep 13, 2026.
What discount rate (WACC) does the fair value of 9544 use?
Our models discount Future Care Trading Co. at 11.8 %: a base by market capitalisation (micro), damped by beta 0.17, country premium for Saudi Arabia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Future Care Trading Co. that is +44.0 % per year a year over ten years, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Future Care Trading Co. (9544) delivered so far?
Over the past 5 years revenue at Future Care Trading Co. grew +5.4 % a year. The price currently implies +44.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Future Care Trading Co. (9544) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into Future Care Trading Co. (+44.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Future Care Trading Co. (9544)?
The free-cash-flow yield on the price is 1.10 %: that much free cash flow Future Care Trading Co. produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Future Care Trading Co. (9544)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Future Care Trading Co. it is 1.38 SAR per share (as of Sep 13, 2026), against a price of 1.53 SAR. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Future Care Trading Co. stock overvalued or undervalued in 2026?
As of Sep 13, 2026, 9544 trades above its calculated fair value: price 1.53 SAR, fair value 1.38 SAR, a gap of about −10% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 9544?
No. The price is what the market pays today (1.53 SAR); the fair value is what the company's own numbers justify (1.38 SAR). For Future Care Trading Co. the two are 0.1500 SAR per share apart. That gap is exactly why we show both numbers side by side.
How much is Future Care Trading Co. worth?
The market values Future Care Trading Co. at about 803M SAR (market capitalisation, as of Sep 13, 2026). Per share that is 1.53 SAR; our models calculate a fair value of 1.38 SAR per share.
What do the bullish and bearish scenarios say about 9544?
Our models span a range for Future Care Trading Co.: cautious scenario 0.8800 SAR, base 1.38 SAR, optimistic 1.68 SAR per share (as of Sep 13, 2026, price 1.53 SAR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 9544?
Future Care Trading Co. trades at a price-to-earnings ratio of 51.0 (as of Sep 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 1.38 SAR is built from several models across several years. Other multiples: P/B 2.2, P/S 2.8, EV/EBITDA 7.4.
How solid is the balance sheet of Future Care Trading Co. (9544)?
Balance-sheet figures for Future Care Trading Co. (as of Sep 13, 2026): return on equity 17.4%. They feed the Quality Score of 67/100, which measures business quality independently of the share price.
How far is 9544 from its 52-week high?
Future Care Trading Co. trades at 1.53 SAR, about 52% below its 52-week high of 3.18 SAR and 2% above the low of 1.50 SAR (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of 1.38 SAR is for.
Which stocks are comparable to Future Care Trading Co.?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, IHH Healthcare Berhad, an investment holding company,, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Future Care Trading Co. stock attractive at the current price?
The data as of Sep 13, 2026: price 1.53 SAR, calculated fair value 1.38 SAR (−10%), Quality Score 67/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 9544 calculated?
We run Future Care Trading Co. through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1.38 SAR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. Future Care Trading Co. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Future Care Trading Co. right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (0.8800 SAR to 1.68 SAR) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Future Care Trading Co.

How large is the market capitalisation of Future Care Trading Co. (9544)?
The market capitalisation of Future Care Trading Co. is 803M SAR (≈ $214M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Future Care Trading Co. (9544)?
The price-to-sales ratio of Future Care Trading Co. is 10.6 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Future Care Trading Co. (9544)?
Earnings per share at Future Care Trading Co. are 0.0300 SAR (price ÷ EPS = P/E 51.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Future Care Trading Co. (9544)?
The net margin of Future Care Trading Co. is 20.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Future Care Trading Co. (9544)?
The return on equity (ROE) of Future Care Trading Co. is 17.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Future Care Trading Co. (9544)?
On an EBIT basis the return on assets of Future Care Trading Co. is 22.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Future Care Trading Co. (9544)?
The operating margin of Future Care Trading Co. is 30.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Future Care Trading Co. (9544)?
Revenue at Future Care Trading Co. is growing +45.5% versus a year earlier (3y avg +30.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Future Care Trading Co. (9544)?
Earnings per share at Future Care Trading Co. are growing +35.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Future Care Trading Co. (9544) hold?
Future Care Trading Co. holds more cash than debt, 56.0M SAR net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Future Care Trading Co. in the live analysis

One click puts Future Care Trading Co. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.